Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NOD2 | Q9HC29 | 4/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | FABP4 | P15090 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2344542 | 0.89 | ELANE (0.39) | ELANENR1H2ALDH1A1TP53TSHR | |
| SCHEMBL2350038 | 0.88 | ELANE (0.43) | ELANEALDH1A1TP53TSHRNOD2 | |
| SCHEMBL2342085 | 0.88 | ELANE (0.40) | ELANENR1H2ALDH1A1NOD2NOD1 | |
| Hydrochloric Acid SCHEMBL2346385 | 0.86 | ELANE (0.42) | ELANEALDH1A1TP53TSHRNOD2 | |
| SCHEMBL2346554 | 0.84 | SMN1; SMN2 (0.44) | ELANEALDH1A1TSHRNOD2NOD1 | |
| Hydrochloric Acid SCHEMBL2349568 | 0.84 | ELANE (0.43) | ELANEALDH1A1TSHRNOD2NOD1 | |
| SCHEMBL2346957 | 0.80 | ELANE (0.40) | ELANEALDH1A1TP53TSHRNOD2 | |
| SCHEMBL2349283 | 0.80 | ELANE (0.43) | ELANEALDH1A1NOD2NOD1MAPT | |
| SCHEMBL2341805 | 0.80 | NOD2 (0.43) | ELANEALDH1A1NOD2NOD1MAPT | |
| SCHEMBL2348931 | 0.80 | NOD2 (0.51) | ELANEALDH1A1NOD2NOD1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008295-B2 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100041652-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-02-18 | — | — | US | disclosed |
| US-20080008708-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2008-01-10 | — | — | US | disclosed |
| EP-1534268-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20060128783-A1 | Tyrosine kinase inhibitors | DINSMORE CHRISTOPHER J | 2006-06-15 | — | — | US | disclosed |
| EP-1534268-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004014300-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128783-A1 | Tyrosine kinase inhibitors | ABL1, ERBB2, JAK2 | ELANE 4439/4885NR1H2 3143/4885ALDH1A1 2298/4885 |
| US-20080008708-A1 | Tyrosine kinase inhibitors | ABL1, ERBB2, JAK2 | ELANE 4439/4885NR1H2 3143/4885ALDH1A1 2298/4885 |
| US-20100041652-A1 | TYROSINE KINASE INHIBITORS | ABL1, ERBB2, JAK2 | ELANE 4439/4885NR1H2 3143/4885ALDH1A1 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.